Acrivon Q3 2026: $77.8M Cash, but Substantial Going-Concern Doubt
ACRV is trading near its 52-week low of $1.27 (14% above the low).
Summary
Acrivon posted a $17.9M net loss for Q3 2026 and held $77.8M in cash, but disclosed substantial doubt about its ability to continue as a going concern within one year of filing.
Key Events · Earnings and Guidance · ACRV
-
Going-Concern Doubt Disclosed
Management determined there is substantial doubt about the company's ability to continue as a going concern within one year after the financial statements are issued; cash is not expected to fund operations beyond 12 months from the filing date.
-
Q3 Loss Narrows to $17.9M
The net loss was $17.9M for the three months ended September 30, 2026, versus $18.2M a year earlier; for the nine months, the net loss was $54.9M versus $58.9M.
-
$77.8M Cash Into Q4 2027
Cash, cash equivalents and investments totaled $77.8M at September 30, 2026, which the company says funds operating expenses and capital expenditures into the fourth quarter of 2027.
-
ATM Sold 4.05M Shares at $1.80
In April 2026 the company issued 4,054,954 shares at $1.80 per share under its ATM program for aggregate gross proceeds of approximately $7.3M; 7,056,101 pre-funded warrants were also exercised into common stock, lifting shares outstanding to 42,908,437 from 31,648,856 at December 31, 2025.
Analysis · ACRV · Life Sciences
The headline for a company with no revenue is the going-concern language, not the quarter itself. Acrivon ended September 30, 2026 with $77.8M in cash, cash equivalents and investments and a $17.9M quarterly net loss, yet management states there is substantial doubt about the company's ability to continue as a going concern within one year of issuing these financial statements. Its cash is not expected to fund operations beyond 12 months from this filing, even though the runway is described as reaching into Q4 2027. That gap matters because the company just added the ACR-525 JAK1 program and a PKCθ program from Aqilion in November 2026, and any new development spending will require fresh capital, most likely equity. The April 2026 ATM already sold 4,054,954 shares at $1.80 for roughly $7.3M gross, and 7,056,101 pre-funded warrants were exercised into common stock during the first quarter, so the share count has climbed to 42.9M from 31.6M at year-end 2025. Cost control is visible — G&A fell to $4.0M from $6.0M and R&D rose only modestly — but that does little to offset the going-concern overhang.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRV was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.6M. The 52-week trading range was $1.27 to $3.56. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.